- Home
- PRCT vs BLTE Comparison
PRCT vs BLTE Comparison
Compare PRCT & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRCT
- BLTE
- Stock Information
- Founded
- PRCT 2009
- BLTE 2018
- Country
- PRCT United States
- BLTE United States
- Employees
- PRCT N/A
- BLTE N/A
- Industry
- PRCT Medical Specialities
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- PRCT Health Care
- BLTE Health Care
- Exchange
- PRCT Nasdaq
- BLTE Nasdaq
- Market Cap
- PRCT 2.1B
- BLTE 2.1B
- IPO Year
- PRCT 2021
- BLTE 2022
- Fundamental
- Price
- PRCT $38.00
- BLTE $66.80
- Analyst Decision
- PRCT Strong Buy
- BLTE Strong Buy
- Analyst Count
- PRCT 8
- BLTE 4
- Target Price
- PRCT $73.63
- BLTE $96.00
- AVG Volume (30 Days)
- PRCT 920.8K
- BLTE 34.8K
- Earning Date
- PRCT 10-27-2025
- BLTE 11-11-2025
- Dividend Yield
- PRCT N/A
- BLTE N/A
- EPS Growth
- PRCT N/A
- BLTE N/A
- EPS
- PRCT N/A
- BLTE N/A
- Revenue
- PRCT $274,950,000.00
- BLTE N/A
- Revenue This Year
- PRCT $48.38
- BLTE N/A
- Revenue Next Year
- PRCT $30.87
- BLTE N/A
- P/E Ratio
- PRCT N/A
- BLTE N/A
- Revenue Growth
- PRCT 55.71
- BLTE N/A
- 52 Week Low
- PRCT $36.90
- BLTE $43.70
- 52 Week High
- PRCT $103.81
- BLTE $86.53
- Technical
- Relative Strength Index (RSI)
- PRCT 39.86
- BLTE 52.34
- Support Level
- PRCT $36.90
- BLTE $65.30
- Resistance Level
- PRCT $39.40
- BLTE $69.69
- Average True Range (ATR)
- PRCT 1.78
- BLTE 2.74
- MACD
- PRCT 0.34
- BLTE 0.30
- Stochastic Oscillator
- PRCT 19.89
- BLTE 39.76
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.